David P Galloway1, Misty L Troutt2, Samuel A Kocoshis2, Andrew T Gewirtz3, Thomas R Ziegler4, Conrad R Cole2. 1. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio David.galloway@cchmc.org. 2. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Center for Inflammation, Immunity, and Infection, Department of Biology, Georgia State University, Atlanta, Georgia. 4. Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Central line-associated bloodstream infections (CLABSIs) pose a significant challenge in the lives of patients with intestinal failure (IF). We hypothesized that plasma immunoglobulins against flagellin (FLiC) and lipopolysaccharide (LPS) would be able to differentiate CLABSIs from nonbacterial febrile episodes and that levels would increase with infection and decline following appropriate antibiotic treatment. MATERIALS AND METHODS: Patients with IF, due to short bowel syndrome, between the ages of 3 months and 4 years of age, were recruited at Cincinnati Children's Hospital Medical Center. Anti-FLiC and anti-LPS plasma antibody levels were measured in 13 children with IF at baseline, during febrile events, and also following treatment with antibiotics. These were also measured in 11 healthy children without IF who were recruited as controls. RESULTS: Plasma anti-FLiC IgA levels increased during febrile episodes in all patients with IF (baseline mean of 1.10 vs febrile episode mean of 1.32 optical density units, respectively; P = .046). Neither plasma anti-FLiC nor anti-LPS IgA or IgG levels distinguished CLABSI from nonbacterial febrile episodes compared with baseline levels. Compared with controls, patients with IF had significantly higher plasma levels of anti-FLiC and anti-LPS IgA at baseline. CONCLUSION: Plasma anti-FLiC IgA antibody levels rise during febrile episodes but do not differentiate between nonbacterial febrile illnesses and CLABSIs in pediatric IF. However, the upregulation of these antibodies in IF suggests the baseline systemic presence of Gram-negative bacterial products.
BACKGROUND: Central line-associated bloodstream infections (CLABSIs) pose a significant challenge in the lives of patients with intestinal failure (IF). We hypothesized that plasma immunoglobulins against flagellin (FLiC) and lipopolysaccharide (LPS) would be able to differentiate CLABSIs from nonbacterial febrile episodes and that levels would increase with infection and decline following appropriate antibiotic treatment. MATERIALS AND METHODS:Patients with IF, due to short bowel syndrome, between the ages of 3 months and 4 years of age, were recruited at Cincinnati Children's Hospital Medical Center. Anti-FLiC and anti-LPS plasma antibody levels were measured in 13 children with IF at baseline, during febrile events, and also following treatment with antibiotics. These were also measured in 11 healthy children without IF who were recruited as controls. RESULTS: Plasma anti-FLiC IgA levels increased during febrile episodes in all patients with IF (baseline mean of 1.10 vs febrile episode mean of 1.32 optical density units, respectively; P = .046). Neither plasma anti-FLiC nor anti-LPS IgA or IgG levels distinguished CLABSI from nonbacterial febrile episodes compared with baseline levels. Compared with controls, patients with IF had significantly higher plasma levels of anti-FLiC and anti-LPS IgA at baseline. CONCLUSION: Plasma anti-FLiC IgA antibody levels rise during febrile episodes but do not differentiate between nonbacterial febrile illnesses and CLABSIs in pediatric IF. However, the upregulation of these antibodies in IF suggests the baseline systemic presence of Gram-negative bacterial products.
Authors: Conrad R Cole; Juliana C Frem; Brian Schmotzer; Andrew T Gewirtz; Jonathan B Meddings; Benjamin D Gold; Thomas R Ziegler Journal: J Pediatr Date: 2010-02-20 Impact factor: 4.406
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Am J Infect Control Date: 2011-05 Impact factor: 2.918
Authors: Emily N Kevan; Julia R Simmons; Samuel A Kocoshis; Mitchell B Cohen; Jeffrey A Rudolph Journal: J Pediatr Gastroenterol Nutr Date: 2011-12 Impact factor: 2.839
Authors: Conrad R Cole; Nellie I Hansen; Rosemary D Higgins; Edward F Bell; Seetha Shankaran; Abbot R Laptook; Michele C Walsh; Ellen C Hale; Nancy S Newman; Abhik Das; Barbara J Stoll Journal: J Pediatr Date: 2011-08-15 Impact factor: 4.406
Authors: Lauren K Barron; James W Bao; Bola G Aladegbami; Jason J Colasanti; Jun Guo; Christopher R Erwin; Brad W Warner Journal: J Pediatr Surg Date: 2017-03-16 Impact factor: 2.545
Authors: Christine M McDonald; Karim P Manji; Kerri Gosselin; Hao Tran; Enju Liu; Rodrick Kisenge; Said Aboud; Wafaie W Fawzi; Andrew T Gewirtz; Christopher P Duggan Journal: Am J Clin Nutr Date: 2016-04-27 Impact factor: 7.045
Authors: Baiyu Yang; Roberd M Bostick; Hao Quang Tran; Andrew T Gewirtz; Peter T Campbell; Veronika Fedirko Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-16 Impact factor: 4.254